DBDjamel Bensmail

Djamel Bensmail

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Djamel Bensmail has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Is Spasticity a Syndrome? A Historical Perspective on Spasticity Definitions and Descriptions

    by Gerard E. Francisco, Thierry Deltombe, Stefano Carda, Rajiv Reebye, Nathalie Draulans, Alessandro Picelli, Bo Biering-Sørensen, Djamel Bensmail, Monica Verduzco-Gutierrez, Michael O’DEll, et al.

    “Spasticity” has long been used as a generalized term for a constellation of distinct positive motor signs arising from a central nervous system lesion, creating ambiguity in identifying individual impairments. These include spasticity sensu stricto – the velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyperexcitability of the stretch reflex, as defined by Lance in 1980 – as well as spastic dystonia, spastic co-contraction, and spasms. Drawing on our clinical experience and collaborative work within the Toxnet group (www.toxnet.net), we believe that using “spasticity” as a broad diagnostic label creates ambiguity and may obscure the specific impairments contributing to the clinical presentation. Such generalization may compromise treatment decisions and outcomes and is compounded by using manual tools like the Tardieu and modified Tardieu Scales, which lack evidence of validity and reliability, and the Ashworth and modified Ashworth Scales, which do not measure the velocity-dependent nature of spasticity or provide dependable insights into the mechanisms driving the torque changes. To optimize clinical assessment precision and treatment outcomes, we propose “spasticity syndrome” as a new umbrella term encompassing the spectrum of clinical manifestations and underlying pathologies associated with upper motor neuron injury, alongside non-neural peripheral changes and patient-reported symptoms.


  • Open Access

    Pathways for Diagnosis and Multimodal Management, Including Botulinum Neurotoxin Therapy, in Shoulder Conditions Following Acquired Central Nervous System Lesions

    by Bo Biering-Sørensen, Carlos Cordero-García, Chris Boulias, Damon Hoad, Djamel Bensmail, Franco Molteni, François Genêt, Jörg Wissel, Jorge Jacinto, Philippe Marque, et al.

    There is limited published guidance available to help less experienced practitioners assess and manage shoulder conditions, including spasticity, after acquired central nervous system (CNS) lesions. To address this gap, 11 spasticity and dystonia experts convened in a 2023 meeting to build on existing guidance, provide consensus on best treatment practice, and develop expert recommendations to guide the diagnosis and treatment of complications of shoulder conditions following CNS lesions. Presentations by each expert on diagnosis and management were followed by discussion; consensus on assessment and treatment practices was identified and recommendations developed. The expert panel recommended an assessment approach structured using the following components: patient history, including interpretation of reported symptoms; observation of postures and pain responses; clinical examination with targeted tests for specific signs; diagnostic tests; and assessment of upper limb impairment, activity limitations, and participation restrictions. This assessment process and the recommended measures recognize the importance of identifying shoulder involvement in upper limb spasticity as part of the diagnostic process in shoulder conditions following CNS lesions. These recommendations provide a practical approach to diagnosis and treatment for clinicians who are less experienced in evaluating and treating such conditions, simplifying otherwise complicated clinical scenarios.

  • Open Access

    Concomitant Botulinum Toxin Injections for Neurogenic Detrusor Overactivity and Spasticity—A Retrospective Analysis of Practice and Safety

    by Arnaud Leilaz, Charles Joussain, Pierre Denys, Djamel Bensmail, Jonathan Levy

    As multiple indications for botulinum toxin injections (BTIs) can coexist for neurological patients, there are to date no description of concomitant injections (CIs) to treat both spasticity and neurogenic detrusor overactivity incontinence (NDOI) in patients with spinal cord injuries (SCIs) and multiple sclerosis (MS). We therefore identified patients followed at our institution by health data hub digging, using a specific procedure coding system in use in France, who have been treated at least once with detrusor and skeletal muscle BTIs within the same 1-month period, over the past 5 years (2017–2021). We analyzed 72 patients representing 319 CIs. Fifty (69%) were male, and the patients were mostly SCI (76%) and MS (18%) patients and were treated by a mean number of CIs of 4.4 ± 3.6 [1–14]. The mean cumulative dose was 442.1 ± 98.8 U, and 95% of CIs were performed within a 72 h timeframe. Among all CIs, five patients had symptoms evocative of distant spread but only one had a confirmed pathological jitter in single-fiber EMG. Eleven discontinued CIs for surgical alternatives: enterocystoplasty (five), tenotomy (three), intrathecal baclofen (two) and neurotomy (one). Concomitant BTIs for treating both spasticity and NDOI at the same time appeared safe when performed within a short delay and in compliance with actual knowledge for maximum doses.


  • Open Access

    Selecting Goals and Target Muscles for Botulinum Toxin A Injection Using the Goal Oriented Facilitated Approach to Spasticity Treatment (GO-FAST) Tool

    by Jorge Jacinto, Alexander Balbert, Djamel Bensmail, Stefano Carda, Nathalie Draulans, Thierry Deltombe, Nicholas Ketchum, Franco Molteni, Rajiv Reebye

    The objective of this article is to introduce the GO-FAST Tool (developed by the Toxnet group) to clinicians working in the field of neurological rehabilitation, specifically post-stroke spasticity management. The concepts utilized in the Tool and described in this article can be broadly grouped into five topics: the principles of patient-centred goal-setting; an algorithm for setting SMART (specific, measurable, attainable, realistic, and timed) treatment goals; goal-related target muscles and botulinum toxin type A dose determinants; goal attainment follow-up, scoring, and interpretation; and the multimodal approach to spasticity management. The Tool can enhance clinical practice by providing guided assistance with goal-setting and target muscle selection for botulinum toxin type A treatment. It also provides support with the follow-up evaluation of goal attainment and calculation of treatment success. The Tool is designed to be used by clinicians with varying levels of expertise in the field of neurological rehabilitation and post-stroke spasticity management, from those who are new to the field to those with many years of experience. A case study is presented in the Results Section of the article to illustrate the utility of the Tool in setting SMART treatment goals in the management of patients with post-stroke spasticity.


  • Open Access

    Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study

    by Djamel Bensmail, Pierre Karam, Anne Forestier, Jean-Yves Loze, Jonathan Lévy

    There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients with MS between 2014 and 2020 in France. This study extracted data from the French National Hospital Discharge Database (Programme de Médicalisation des Systèmes d’Information, PMSI) covering the entire French population. Among 105,206 patients coded with MS, we identified those who received ≥1 BoNT-A injection, administered within striated muscle for MS-related spasticity and/or within the detrusor smooth muscle for neurogenic detrusor overactivity (NDO). A total of 8427 patients (8.0%) received BoNT-A injections for spasticity, 52.9% of whom received ≥3 BoNT-A injections with 61.9% of the repeated injections administered every 3 to 6 months. A total of 2912 patients (2.8%) received BoNT-A injections for NDO, with a mean of 4.7 injections per patient. Most repeated BoNT-A injections within the detrusor smooth muscle (60.0%) were administered every 5 to 8 months. There were 585 patients (0.6%) who received both BoNT-A injections within striated muscle and the detrusor smooth muscle. Overall, our study highlights a broad range of BoNT-A treatment practices between 2014 and 2020 in patients with MS.


  • Open Access

    Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study

    by Ines Baccouche, Djamel Bensmail, Emilie Leblong, Bastien Fraudet, Claire Aymard, Victorine Quintaine, Sandra Pottier, Thibaud Lansaman, Claire Malot, Philippe Gallien, et al.

    Spasticity is one of the most disabling symptoms in multiple sclerosis (MS). Botulinum toxin injection (BTI) is a first-line treatment for focal spasticity. There is a lack of evidence of a functional improvement following BTI in MS-related spasticity. To describe goal-setting for BTI in MS, and evaluate the degree of attainment, using goal attainment scaling (GAS) 4-to-6 weeks after injection session, a one-year multi-center retrospective observational study assessing goal-setting and achievement during BTI session in spastic patients with MS was set up. Following the GAS method, patients and their physicians set up to three goals and scored their achievement 4 to 6 weeks thereafter. Commonly used goals from three centers were combined into a standardized list and 125 single BTI sessions were analyzed. The most frequent goals regarded lower limb (LL) impairments (equinovarus foot, toe claw) or locomotion (stability, walking distance, clinging) and accounted for 89.1%, versus 10.9% for upper limb (UL), mostly for mild-to-moderate MS. Overall, goals were frequently achieved (85.77%) mainly when related to gait and mobility rather than hygiene and ease of care. This study gives an overview on the most frequent, relevant, and achievable goals to be set in real-life practice of BTI for spasticity management in MS.


  • Spasticity or periodic limb movements? Lessons from a not-uncommon case report

    by Jonathan Levy, Thibaud Lansaman, Flavie Frémondière, Anne-Laure Ferrapie, Avigaelle Sher, Mickael Dinomais, Djamel Bensmail


  • Does botulinum toxin treatment improve upper limb active function?

    by Jonathan Levy, Franco Molteni, Giovanni Cannaviello, Thibaud Lansaman, Nicolas Roche, Djamel Bensmail


  • Efficacy of incobotulinumtoxinA for treatment of lower limb spasticity, including pes equinovarus, in adults

    by Djamel Bensmail, Jörg Wissel, Olivier Simon, Astrid Scheschonka, Birgit Flatau-Baqué, Dirk Dressler, David M. Simpson